UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Delta-like 4 Notch Ligand Regulates Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth In vivo

Cancer research (Chicago, Ill.), 2007-12, Vol.67 (23), p.11244-11253

2007

Volltextzugriff (PDF)

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

BMC cardiovascular disorders, 2022-02, Vol.22 (1), p.49-16, Article 49

2022

Volltextzugriff (PDF)

195 Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: using quantitative systems pharmacology (QSP) modelling in the development of CDR404 for solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A223-A223

2023

Volltextzugriff (PDF)

Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma

Pediatric blood & cancer, 2012-03, Vol.58 (3), p.327-333

2012

Volltextzugriff (PDF)

Analysis of Cardiac Amyloidosis Progression Using Model-Based Markers

Frontiers in physiology, 2020-04, Vol.11, p.324-324

2020

Volltextzugriff (PDF)

1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1552-A1552

2023

Volltextzugriff (PDF)

Cytoreductive Nephrectomy in Metastatic Clear‐Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era

The oncologist (Dayton, Ohio), 2009-01, Vol.14 (1), p.52-59

2009

Volltextzugriff (PDF)

Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor

Frontiers in oncology, 2015-10, Vol.5 (Article 236), p.236

2015

Volltextzugriff (PDF)

Effects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts

Journal of oncology, 2010, Vol.2010, p.1-14

2010

Volltextzugriff (PDF)

Non-glucose metabolism in cancer cells—is it all in the fat?

Cancer and metastasis reviews, 2012-12, Vol.31 (3-4), p.689-698

2012

Volltextzugriff (PDF)

Immunotherapeutic strategies in kidney cancer-when TKIs are not enough

Nature reviews. Clinical oncology, 2009-08, Vol.6 (8), p.478-487

2009

Volltextzugriff (PDF)

Autologous T cell therapy for MAGE-A4 + solid cancers in HLA-A02 + patients: a phase 1 trial

Nature medicine, 2023-01, Vol.29 (1), p.104-114

2023

Volltextzugriff (PDF)

Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11562-11562

2022

Volltextzugriff (PDF)

SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11504-11504

2021

Volltextzugriff (PDF)

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

The Lancet (British edition), 2024-04, Vol.403 (10435), p.1460-1471

2024

Volltextzugriff (PDF)

DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS8552-TPS8552

2020

Volltextzugriff (PDF)

SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS11569-TPS11569

2020

Volltextzugriff (PDF)

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Blood, 2019-11, Vol.134 (Supplement_1), p.1857-1857

2019

Volltextzugriff (PDF)

LBO12 - Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells

Journal of hepatology, 2020-08, Vol.73, p.S122-S122

2020

Volltextzugriff (PDF)

Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells

Journal of hepatology, 2020-08, Vol.73, p.S122

2020

Volltextzugriff (PDF)

Abstract LB442: Novel antibodies against a KK-LC-1-derived peptide presented on HLA-A01 on tumor cells

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.LB442-LB442

2024

Volltextzugriff (PDF)

Abstract A023: Identifying new therapeutic indications for afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4]) in adult and pediatric sarcomas using MAGE-A4 immunohistochemistry

Clinical cancer research, 2022-09, Vol.28 (18_Supplement), p.A023-A023

2022

Volltextzugriff (PDF)

The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins

Expert opinion on investigational drugs, 2014-05, Vol.23 (5), p.629-645

2014

Volltextzugriff (PDF)

CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC

Carcinogenesis (New York), 2012-09, Vol.33 (9), p.1717-1725

2012

Volltextzugriff (PDF)

Abstract A038: Enrollment of pediatric and adolescent patients with MAGE-A4+ advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4])

Clinical cancer research, 2022-09, Vol.28 (18_Supplement), p.A038-A038

2022

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(35)
Berichte
(1)

Sprache

Englisch
(36)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(13)
Oncology
(10)
Tumors
(6)
Adult
(5)
Animals
(5)
Immunotherapy
(5)
Biological And Medical Sciences
(4)
Cancer
(4)
Medical Sciences
(4)
Aged
(3)
Angiogenesis Inhibitors - Therapeutic Use
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Carcinoma, Renal Cell - Drug Therapy
(3)
Female
(3)
Kidney Neoplasms - Drug Therapy
(3)
Kidney Neoplasms - Pathology
(3)
Male
(3)
Metastases
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Delta-like 4 Notch Ligand Regulates Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth In vivo

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

195 Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: using quantitative systems pharmacology (QSP) modelling in the development of CDR404 for solid tumors

Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma

Analysis of Cardiac Amyloidosis Progression Using Model-Based Markers

1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

Cytoreductive Nephrectomy in Metastatic Clear‐Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era

Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor

Effects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts

Non-glucose metabolism in cancer cells—is it all in the fat?

Immunotherapeutic strategies in kidney cancer-when TKIs are not enough

Autologous T cell therapy for MAGE-A4 + solid cancers in HLA-A02 + patients: a phase 1 trial

Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials

SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM)

SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

LBO12 - Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells

Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells

Abstract LB442: Novel antibodies against a KK-LC-1-derived peptide presented on HLA-A01 on tumor cells

Abstract A023: Identifying new therapeutic indications for afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4]) in adult and pediatric sarcomas using MAGE-A4 immunohistochemistry

The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins

CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC

Abstract A038: Enrollment of pediatric and adolescent patients with MAGE-A4+ advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4])

Suchergebnisse filtern